Fig 1: The constructed nomogram for prognostic prediction of patients with LUAD. (A) A nomogram for predicting the 3- and 5-year survival probability of patients with LUAD; (B) calibration curve showing nomogram performance (3-year); (C) calibration curve showing nomogram performance (5-year). EHD2, EH domain contains protein 2; OS, overall survival; LUAD, lung adenocarcinoma.
Fig 2: Co-expression analysis of EHD2. (A) The top 20 genes whose co-expression was positive and negative with EHD2; (B) KEGG enrichment analysis; (C) GO analysis. EHD2, EH domain contains protein 2; BP, biological processes; CC, cellular components; MF, molecular functions; KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology.
Fig 3: EHD2 expression affects lung adenocarcinoma migration and invasion ability. (A) The expression of EHD2 in LUAD cells and shRNA-mediated EHD2 knockdown cells; (B) Phagokinetic motility assays in H1299 and A549 cells (100×); (C) Transwell in A549 cells; (D) Transwell in H1299 cells; (E) the expression of EHD2, E-cadherin, N-cadherin, and Vimentin were explored by western blot. All crystal violet staining sections were imaged at 100× magnification (C,D). **, P<0.01 vs. control; ***, P<0.005 vs. control. EHD2, EH domain contains protein 2; GD, GAPDH; NC, normal control; E-ca, E-cadherin; N-ca, N-cadherin; Vim, Vimentin; LUAD, lung adenocarcinoma.
Fig 4: Integrated analysis of LUAD reveals that EHD2 may be a biomarker. (A) GEPIA analyzes of the expression of EHD2 in LUAD.Red represents tumor tissue group, and black represents adjacent normal tissue group; (B) GEPIA analyzes the correlation between EHD2 and CDH1; (C) Kaplan-Meier plotter analysis of the relationship between EHD2 and the prognosis of LUAD patients; (D) GSEA-KEGG pathway analysis. *, P<0.05. TPM, transcripts per million; LUAD, lung adenocarcinoma; T, tumor; N, normal; EHD2, EH domain contains protein 2; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; GEPIA, Gene Expression Profiling Interactive Analysis; GSEA-KEGG, gene set enrichment analysis-Kyoto Encyclopedia of Genes and Genomes.
Fig 5: Association of EHD2 expression with the overall survival of HCC patients by Kaplan-Meier analysis. (A) All sample; (B) patients who have received radiotherapy; (C) patients who have not received radiotherapy. EHD2, EH domain contains protein 2; HCC, hepatocellular carcinoma.
Supplier Page from Abcam for Anti-EHD2 antibody